Erectile dysfunction (ED) is fundamentally a vascular problem for most men who experience it, which is exactly why some people ask whether a fibrinolytic, circulation-focused supplement like nattokinase could help. The connection is biologically reasonable to raise, but it is important to be precise about where the evidence actually stands.
Key Takeaways
- No clinical trial has ever tested nattokinase specifically for erectile function as an outcome; this connection is a theoretical extrapolation, not an evidence-based treatment claim.
- An erection is a neurovascular event dependent on healthy arterial inflow to the corpora cavernosa, and ED often shows up years before a diagnosed cardiac event because the penile arteries are smaller and more sensitive to early atherosclerosis than coronary arteries.
- Nattokinase has some evidence for three related cardiovascular mechanisms, though each is limited: a mixed blood pressure signal, fibrinolytic (clot-dissolving) activity seen in lab and small human studies, and a von Willebrand factor drop that was only a statistical trend in one trial [3][4][2].[2]
- A 2024 study found nattokinase pretreatment reduced vascular endothelial inflammation and adhesion molecule levels in animal models, a mechanism relevant to the endothelial dysfunction that underlies most vascular ED.
- ED is frequently an early warning sign of systemic cardiovascular disease and should prompt a medical workup, not just a supplement trial.
This post contains affiliate links. As an Amazon Associate, NattokinaseHub earns from qualifying purchases at no extra cost to you.
Why the Question Comes Up at All
An erection is a neurovascular event: nerve signals trigger relaxation of smooth muscle in the corpora cavernosa, arterial blood flows in, and venous outflow is restricted to maintain rigidity. Anything that compromises arterial blood flow, whether atherosclerosis, hypertension, diabetes, or endothelial dysfunction, can interfere with that process. Because the penile arteries are smaller than coronary arteries, they tend to show blockage-related symptoms earlier than the heart does. That is why urologists often describe ED as an early cardiovascular warning sign, sometimes preceding a diagnosed cardiac event by years. Given that nattokinase has documented cardiovascular effects, it is a reasonable question to ask whether those effects extend to erectile blood flow specifically.
What Nattokinase’s Cardiovascular Evidence Actually Covers
Nattokinase’s best-supported effects are a pooled systolic blood pressure drop of 3.45 mmHg in a 2023 meta-analysis that rested on only a few small trials, fibrinolytic activity through several pathways shown mostly in lab studies (such as cleaving PAI-1), and a von Willebrand factor drop that was only a statistical trend in one trial [5][3][2].[1] Separately, a 2024 study found that nattokinase pretreatment in animal models reduced circulating adhesion molecules and vascular inflammation following TNF-alpha exposure, a mechanism tied to endothelial dysfunction, the same underlying process implicated in vascular ED. These effects are documented mainly as short-term markers, and the longest randomized trial, in 265 healthy adults over a median of 3 years, found no effect on blood pressure or carotid artery thickening [4]. None of them, however, have been tested with erectile function as the measured outcome in a clinical trial.
The Gap Between Plausible and Proven
A patent filing exists that mentions nattokinase’s potential use for circulation-related erectile issues, describing reduced fibrin buildup in blood vessels as a possible mechanism for improving penile blood supply. A patent application is not clinical evidence; it reflects a proposed use, not a tested and published outcome. No randomized controlled trial, and no published case series, has measured erectile function, using a validated tool like the International Index of Erectile Function or similar, in men taking nattokinase. That is a meaningful gap, and it separates nattokinase from ED-specific interventions like PDE5 inhibitors (sildenafil and similar drugs) or L-citrulline, which do have direct trial data for erectile outcomes.
What This Means in Practice
If vascular health is your actual goal, nattokinase’s blood pressure and circulatory research is relevant background, but it should not be framed or purchased as an ED treatment. Men experiencing new or worsening ED, particularly if it is sudden or accompanied by chest pain, shortness of breath, or other cardiovascular symptoms, should see a physician for a cardiovascular workup rather than self-treating with a circulation supplement, given how often ED is the first visible sign of a larger vascular problem worth catching early.
Frequently Asked Questions
Does nattokinase help with erectile dysfunction?
There is no clinical trial evidence testing nattokinase specifically for erectile function. The connection is based on general vascular physiology and nattokinase’s documented blood pressure and circulatory effects, not on any study that measured erections as an outcome.
Why do doctors say ED can be an early sign of heart disease?
The arteries supplying the penis are smaller than coronary arteries, so early atherosclerosis tends to reduce blood flow there first, sometimes years before a cardiac event is diagnosed. This is why new-onset ED, especially in middle-aged men, often prompts a cardiovascular evaluation.
Is there a patent related to nattokinase and erectile dysfunction?
Yes, a patent application mentions using nattokinase to address fibrin-related circulation issues that could affect penile blood supply. A patent filing describes a proposed use; it is not clinical trial evidence and should not be treated as proof of efficacy.
What has stronger evidence for erectile dysfunction than nattokinase?
PDE5 inhibitors (prescription medications like sildenafil) have extensive randomized trial data specifically for erectile function. L-citrulline also has direct, though more modest, clinical trial evidence for ED. Neither comparison diminishes nattokinase’s separate, real cardiovascular research; it simply reflects what has and has not been directly tested for this specific outcome.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Always talk to your doctor before starting nattokinase, especially if you take blood thinners or have an upcoming surgery.
References
- Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. International Journal of Molecular Sciences (2017). PMID 28264497
- Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine (2023). PMID 39076715
- Jensen GS et al. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integrated blood pressure control (2016). PMID 27785095
- Hodis HN et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical hemorheology and microcirculation (2021). PMID 33843667
- Tetsumei Urano et al. The Profibrinolytic Enzyme Subtilisin NAT Purified fromBacillus subtilis Cleaves and Inactivates Plasminogen Activator Inhibitor Type 1. Journal of Biological Chemistry (2001). PMID 11325965
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
